Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19

The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamouche, Walid, Bisserier, Malik, Brojakowska, Agnieszka, Eskandari, Abrisham, Fish, Kenneth, Goukassian, David A., Hadri, Lahouaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833205/
https://www.ncbi.nlm.nih.gov/pubmed/33373644
http://dx.doi.org/10.1016/j.yjmcc.2020.12.009
_version_ 1783642012618063872
author Hamouche, Walid
Bisserier, Malik
Brojakowska, Agnieszka
Eskandari, Abrisham
Fish, Kenneth
Goukassian, David A.
Hadri, Lahouaria
author_facet Hamouche, Walid
Bisserier, Malik
Brojakowska, Agnieszka
Eskandari, Abrisham
Fish, Kenneth
Goukassian, David A.
Hadri, Lahouaria
author_sort Hamouche, Walid
collection PubMed
description The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), its unusual and divergent presentation has strengthened the status of COVID-19 as a major public health threat. In this review, we aim to 1- discuss the epidemiological data from various COVID-19 patient cohorts around the world and the USA as well the associated risk factors; 2- summarize the pathophysiology of SARS-CoV-2 infection and the underlying molecular mechanisms for the respiratory and cardiovascular manifestations; 3- highlight the potential treatments and vaccines as well as current clinical trials for COVID-19.
format Online
Article
Text
id pubmed-7833205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78332052021-01-26 Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19 Hamouche, Walid Bisserier, Malik Brojakowska, Agnieszka Eskandari, Abrisham Fish, Kenneth Goukassian, David A. Hadri, Lahouaria J Mol Cell Cardiol Article The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), its unusual and divergent presentation has strengthened the status of COVID-19 as a major public health threat. In this review, we aim to 1- discuss the epidemiological data from various COVID-19 patient cohorts around the world and the USA as well the associated risk factors; 2- summarize the pathophysiology of SARS-CoV-2 infection and the underlying molecular mechanisms for the respiratory and cardiovascular manifestations; 3- highlight the potential treatments and vaccines as well as current clinical trials for COVID-19. Published by Elsevier Ltd. 2021-04 2020-12-26 /pmc/articles/PMC7833205/ /pubmed/33373644 http://dx.doi.org/10.1016/j.yjmcc.2020.12.009 Text en © 2020 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hamouche, Walid
Bisserier, Malik
Brojakowska, Agnieszka
Eskandari, Abrisham
Fish, Kenneth
Goukassian, David A.
Hadri, Lahouaria
Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title_full Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title_fullStr Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title_full_unstemmed Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title_short Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
title_sort pathophysiology and pharmacological management of pulmonary and cardiovascular features of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833205/
https://www.ncbi.nlm.nih.gov/pubmed/33373644
http://dx.doi.org/10.1016/j.yjmcc.2020.12.009
work_keys_str_mv AT hamouchewalid pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT bisseriermalik pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT brojakowskaagnieszka pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT eskandariabrisham pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT fishkenneth pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT goukassiandavida pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19
AT hadrilahouaria pathophysiologyandpharmacologicalmanagementofpulmonaryandcardiovascularfeaturesofcovid19

Ejemplares similares